logo
Plus   Neg
Share
Email

Danaher Withdraws FY20 Outlook Amid COVID-19 - Quick Facts

Danaher Corp. (DHR) announced Monday that it is withdrawing its financial guidance for the full year 2020, which was provided on January 30, 2020, due to the evolving and uncertain impact of the coronavirus (COVID-19) pandemic.

The company will report first quarter 2020 financial results on Thursday, May 7, 2020. It expects revenue growth of approximately 3.0 percent and adjusted core revenue growth of approximately 4.5 percent for the first quarter.

The company said it anticipates positive results in each of its three reporting segments in the first quarter, with particular strength in its Cepheid, Radiometer, Pall and ChemTreat businesses.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that the current state of the COVID-19 pandemic in the U.S. is "really not good." The U.S. is the country worst-affected by the coronavirus and has recently seen a surge in coronavirus infections as lockdown restrictions are eased. Granules Pharmaceuticals, Inc. recalled twelve (12) lots of type 2 diabetes medication Metformin hydrochloride Extended-Release, in the form of oral film-coated tablets, for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Palantir Technologies Inc., the Silicon Valley big data analytics company that has handled U.S. government's certain sensitive projects, said it has confidentially filed documents with the Securities and Exchange Commission to go public. In a statement, the company said the proposed public listing of its Class A common stock is expected to take place after the SEC completes its review process.
Follow RTT